Reata Pharmaceuticals, Inc.
RETA · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $2,216 | $11,490 | $9,019 | $26,517 |
| % Growth | -80.7% | 27.4% | -66% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $124,398 |
| Gross Profit | $2,216 | $11,490 | $9,019 | -$97,881 |
| % Margin | 100% | 100% | 100% | -369.1% |
| R&D Expenses | $169,843 | $155,993 | $159,080 | $128,109 |
| G&A Expenses | $109,277 | $99,002 | $75,128 | $58,298 |
| SG&A Expenses | $109,277 | $99,002 | $75,128 | $58,298 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1,130 | $1,203 | $1,136 | $932 |
| Operating Expenses | $280,250 | $256,198 | $235,344 | $187,339 |
| Operating Income | -$270,155 | -$244,708 | -$226,325 | -$285,220 |
| % Margin | -12,191.1% | -2,129.7% | -2,509.4% | -1,075.6% |
| Other Income/Exp. Net | -$33,892 | -$53,128 | -$43,914 | -$4,942 |
| Pre-Tax Income | -$311,926 | -$297,836 | -$270,239 | -$290,162 |
| Tax Expense | -$25 | -$450 | -$22,487 | $8 |
| Net Income | -$311,901 | -$297,386 | -$247,752 | -$290,170 |
| % Margin | -14,075% | -2,588.2% | -2,747% | -1,094.3% |
| EPS | -8.59 | -8.19 | -7.35 | -9.54 |
| % Growth | -4.9% | -11.4% | 23% | – |
| EPS Diluted | -8.59 | -8.19 | -7.35 | -9.54 |
| Weighted Avg Shares Out | 36,321 | 36,321 | 33,709 | 30,414 |
| Weighted Avg Shares Out Dil | 36,321 | 36,321 | 33,709 | 30,414 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,990 | $177 | $0 | $0 |
| Interest Expense | $41,771 | $53,251 | $36,779 | $11,197 |
| Depreciation & Amortization | $1,130 | $1,203 | $1,136 | $932 |
| EBITDA | -$269,025 | -$243,505 | -$232,324 | -$278,033 |
| % Margin | -12,140.1% | -2,119.3% | -2,575.9% | -1,048.5% |